Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
15. Oktober 2019 08:30 ET
|
Emerald Bioscience, Inc.
Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....
Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting
03. Oktober 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Emerald Bioscience to Participate in Investment and Scientific Conferences in September
27. August 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
26. August 2019 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study
13. August 2019 08:30 ET
|
Emerald Bioscience, Inc.
Pre-clinical studies of cannabidiol analog to commence Long Beach, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development...
Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)
19. Juni 2019 07:00 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
04. Juni 2019 08:00 ET
|
Emerald Bioscience, Inc.
Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald...
Emerald Bioscience to Present at the 9th Annual LD Micro Invitational
03. Juni 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi
29. Mai 2019 08:00 ET
|
Emerald Bioscience, Inc.
Licenses Permit Emerald to Develop THC-Prodrug and CBD-Analog for Any Therapeutic Indication by Any Route of Administration for Human and Veterinary Use LONG BEACH, CA, May 29, 2019 (GLOBE...
Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
13. Mai 2019 08:00 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...